Loading...
•
Mar 31
Quanterix Q1 2025 Earnings Report
Reported financial results for the first quarter ended March 31, 2025.
Key Takeaways
Quanterix reported Q1 2025 revenue of $30.3 million, a 5% decrease year-over-year, and a net loss of $20.5 million, wider than the prior year. The company announced strategic initiatives, including a new Simoa ONE assay kit compatible with existing flow cytometers to expand market reach, and cost reduction measures targeting $30 million in annual savings to achieve positive cash flow by 2026. They also provided full-year 2025 revenue guidance of $120 million to $130 million.
Total revenue for Q1 2025 was $30.3 million, a decrease of 5% compared to $32.1 million in Q1 2024.
GAAP Net loss for Q1 2025 was $20.5 million, compared to a net loss of $11.2 million in Q1 2024.
The company ended the quarter with $269.5 million in cash, cash equivalents, marketable securities, and restricted cash.
Quanterix is implementing cost reduction initiatives to achieve $30 million in annual savings and aims to generate positive cash flow by 2026.
Quanterix
Quanterix
Quanterix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comService and Other Revenue
CapyFin.comCollaboration and License Revenue
CapyFin.comGrant Revenue
CapyFin.com Forward Guidance
For the full year 2025, excluding the planned acquisition of Akoya and Lucent Diagnostics testing revenue, Quanterix expects revenues between $120 million and $130 million, representing a year-over-year decline of 5% to 13%. GAAP gross margin is expected to be in the range of 55% to 59%, and adjusted gross margin (non-GAAP) between 50% and 54%. Adjusted cash burn is anticipated to be approximately $35.0 million to $45.0 million.
Positive Outlook
- Expected GAAP gross margin range of 55% to 59%.
- Expected adjusted gross margin (non-GAAP) range of 50% to 54%.
- Targeting positive cash flow by 2026 with a cash balance exceeding $100 million.
- Implementation of cost reduction initiatives to achieve $30 million in annual savings.
- Planned acquisition of Akoya Biosciences expected to close in June 2025.
Challenges Ahead
- Full-year 2025 revenue guidance represents a year-over-year decline of 5% to 13%.
- Guidance reflects recent cuts to academic research funding.
- Guidance reflects biopharma spending patterns.
- Guidance reflects impacts from tariffs.
- Anticipated 2025 adjusted cash burn of approximately $35.0 million to $45.0 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income